Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci

Antimicrob Agents Chemother. 2006 Jul;50(7):2583-6. doi: 10.1128/AAC.01432-05.

Abstract

Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and beta-hemolytic streptococci. The MIC90 results for retapamulin were 0.12 microg/ml for Staphylococcus aureus and < or = 0.03 microg/ml for Streptococcus pyogenes; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Bridged Bicyclo Compounds, Heterocyclic / chemistry
  • Bridged Bicyclo Compounds, Heterocyclic / pharmacology*
  • Diterpenes / pharmacology
  • Drug Resistance, Bacterial*
  • Gram-Positive Cocci / drug effects*
  • Humans
  • Microbial Sensitivity Tests
  • Pleuromutilins
  • Polycyclic Compounds
  • Staphylococcus aureus / drug effects
  • Streptococcus pyogenes / drug effects

Substances

  • Anti-Bacterial Agents
  • Bridged Bicyclo Compounds, Heterocyclic
  • Diterpenes
  • Polycyclic Compounds
  • retapamulin